Items where authors include "Morley, N.J."

Article

Katz, D.A., Morris, J.D., Chu, M.P. et al. (17 more authors) (2022) Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL. Leukemia & Lymphoma, 63 (9). pp. 2063-2073. ISSN 1042-8194

Colton, H. orcid.org/0000-0002-3287-4103, Greenfield, D.M. orcid.org/0000-0002-3733-2717, Snowden, J.A. orcid.org/0000-0001-6819-3476 et al. (6 more authors) (2021) Long-term survivors following autologous haematopoetic stem cell transplantation have significant defects in their humoral immunity against vaccine preventable diseases, years on from transplant. Vaccine, 39 (34). pp. 4778-4783. ISSN 0264-410X

Griffin, J. orcid.org/0000-0003-3969-7637, Allsobrook, O., Khurram, S.A. orcid.org/0000-0002-0378-9380 et al. (3 more authors) (2018) EBV-associated ulceration in an immunocompromised patient. Diagnostic Histopathology, 24 (7). pp. 267-271. ISSN 1756-2317

Morley, N.J. and Marks, D.I. (2016) Inotuzumab ozogamicin in the management of acute lymphoblastic leukaemia. Expert Review of Anticancer Therapy, 16 (2). pp. 159-164. ISSN 1473-7140

Proceedings Paper

Coyle, L., Morley, N.J. orcid.org/0000-0002-0497-975X, Rambaldi, A. et al. (6 more authors) (2018) Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-hodgkin lymphoma. In: Blood. 60th ASH Annual Meeting, 01-04 Dec 2018, San Diego, CA, USA. American Society of Hematology , p. 400.